Dosing Schedule for Retatrutide: Trial Data, Safety and UK Status The dosing schedule for retatrutide is a key question for clinicians and patients following the promising Phase 2 trial results published in 2023
Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, et al
Trulicity users typically experience more modest weight changes, averaging 5% to 10% of body weight
Could reach more patients Leggio, who is leading an ongoing trial of semaglutide for alcohol use disorder, highlighted that GLP-1 drugs could reach patients who otherwise go untreated
Communicating openly about your experience during follow-up appointments ensures your PlexusDx provider can personalize your protocol for maximum benefit with minimal disruption to your daily life